HIGH POINT, N.C.--(BUSINESS WIRE)--Dec. 21, 2017--
vTv
Therapeutics Inc. (Nasdaq:VTVT) today announced that vTv
Therapeutics LLC has entered into a global licensing agreement with
Reneo Pharmaceuticals, a privately-held biotechnology company focused on
developing treatments for orphan diseases. The agreement grants Reneo
Pharmaceuticals exclusive worldwide rights to research, develop and
commercialize vTv Therapeutics’ selective peroxisome
proliferator-activated receptor delta (PPAR-delta) program. Under the
terms of the agreement, vTv Therapeutics will receive an upfront payment
and will be eligible to receive future development and commercialization
milestones as well as royalties on sales of approved products. vTv
Therapeutics will also receive shares of Reneo Pharmaceuticals' common
stock.
HPP593, a functionally selective PPAR-delta agonist, has demonstrated a
lowering of low-density lipoprotein cholesterol and triglycerides in
animal models and humans, with a significant increase in high-density
lipoprotein cholesterol. HPP593 has also demonstrated an anti-diabetic
effect in several animal models of type 2 diabetes. Phase 1 studies have
shown HPP593 to be well tolerated.
“We’re thrilled to partner with Reneo and the company’s founder and
executive chairman, Mike Grey, an established and recognized leader in
the industry, to complete the development and commercialization of our
PPAR-delta program,” said Steve Holcombe, president and chief executive
officer of vTv Therapeutics. “This collaboration represents continued
delivery on our commitment to translate innovative science into medicine
for patients, and Reneo Pharmaceuticals' expertise makes it well suited
to maximize the potential of this candidate.”
About vTv Therapeutics
vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company
engaged in the discovery and development of orally administered small
molecule drug candidates to fill significant unmet medical needs. vTv
has a pipeline of clinical drug candidates led by programs for the
treatment of Alzheimer’s disease and diabetes as well as treatment of
inflammatory disorders and the prevention of muscle weakness.
Forward-Looking Statements
This release contains forward-looking statements, which involve risks
and uncertainties. These forward-looking statements can be identified by
the use of forward-looking terminology, including the terms
“anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,”
“plan,” “potential,” “predict,” “project,” “should,” “target,” “will,”
“would” and, in each case, their negative or other various or comparable
terminology. All statements other than statements of historical facts
contained in this release, including statements regarding the timing of
our clinical trials, our strategy, future operations, future financial
position, future revenue, projected costs, prospects, plans, objectives
of management and expected market growth are forward-looking statements.
These statements involve known and unknown risks, uncertainties and
other important factors that may cause our actual results, performance
or achievements to be materially different from any future results,
performance or achievements expressed or implied by the forward-looking
statements. Important factors that could cause our results to vary from
expectations include those described under the heading “Risk Factors” in
our Annual Report on Form 10-K and our other filings with the SEC. These
forward-looking statements reflect our views with respect to future
events as of the date of this release and are based on assumptions and
subject to risks and uncertainties. Given these uncertainties, you
should not place undue reliance on these forward-looking statements.
These forward-looking statements represent our estimates and assumptions
only as of the date of this release and, except as required by law, we
undertake no obligation to update or review publicly any forward-looking
statements, whether as a result of new information, future events or
otherwise after the date of this release. We anticipate that subsequent
events and developments will cause our views to change. Our
forward-looking statements do not reflect the potential impact of any
future acquisitions, merger, dispositions, joint ventures or investments
we may undertake. We qualify all of our forward-looking statements by
these cautionary statements.
View source version on businesswire.com: http://www.businesswire.com/news/home/20171221005970/en/
Source: vTv Therapeutics Inc.
Investors:
vTv Therapeutics Inc.
Mike Biega, 617-221-9660
IR@vtvtherapeutics.com
or
Media:
Pure
Communications
Katie Engleman, 910-509-3977
Katie@purecommunications.com
